Table 1.

Effects of combined treatment with rofecoxib/nimesulide and MK886, LY171883, or FB1 on caspase-3 activity in the HT29 and Caco-2 colon cancer cells

DrugsCaspase-3 activity (units/mg protein)
HT29 cellsCaco-2 cells
None149.9 ± 2.7110.3 ± 2.0
Rofecoxib (10 μmol/L)128.8 ± 8.1123.1 ± 5.3
Nimesulide (10 μmol/L)141.6 ± 4.0128.7 ± 1.1
MK886 (10 μmol/L)172.8 ± 1.9142.7 ± 2.8
LY171883 (10 μmol/L)160.7 ± 1.3125.8 ± 3.2
FB1 (10 μmol/L)129.6 ± 1.7109.9 ± 3.4
Rofecoxib + MK886309.3 ± 9.2*,330.0 ± 6.2*,
Nimesulide + MK886319.1 ± 12.4*,334.2 ± 4.4*,
Rofecoxib + LY171883307.7 ± 3.4*,297.4 ± 5.0*,
Nimesulide + LY171883304.4 ± 2.1*,300.8 ± 6.3*,
Rofecoxib + MK886 + FB1140.1 ± 1.1147.8 ± 4.9
Nimesulide + MK886 + FB1144.6 ± 5.0147.3 ± 3.2
  • * Significant increase compared with basal condition (P < 0.05).

  • Significant increase compared with treatment with rofecoxib, nimesulide, MK886, or LY171883 alone (P < 0.05).

  • Significant decrease compared with treatment with rofecoxib/nimesulide + MK886 (P < 0.05).